Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces it will be holding a webinar for investors, analysts, and media on 9th May 2024 at 10.00 EST/15.00 GMT/16.00 CET.
The event will provide a deeper insight into the Company, its strategy and lead pipeline assets. Speakers will include Peter Jackson, Chief Executive Officer; Dawn Watson, Chief Financial Officer; Prof. Colm Leonard, Chief Medical Officer and Dr Victoria Savage, Chief Scientific Officer. There will also be an opportunity for attendees to take part in a Q&A.
Infex is a leader in critical-priority infectious diseases with a broad and diverse pipeline of innovative best-in-class and first-in-class drug candidates to address the urgent global shortage of novel anti-infective treatments. Its lead candidates include:
- RESP-X: A phase II, first-in-class anti-virulence antibody targeting chronic Pseudomonas aeruginosa (Pa) bacterial infections in respiratory diseases, initially as a long-term preventative treatment for Non-Cystic Fibrosis Bronchiectasis (NCFB), a chronic and debilitating respiratory disease for which there are currently no approved treatments. There is potential to expand into cystic fibrosis and COPD.
- MET-X: A phase I ready, best-in-class metallo-beta-lactamase (“MBL”) inhibitor, in development to be one of the first broad-spectrum MBL inhibitors that blocks MBL antibiotic resistance to restore the antibiotic activity of beta-lactam drugs.
- COV-X: A novel first-in-class small molecule oral pan-coronavirus antiviral candidate that has potential for broad spectrum efficacy against coronaviruses with pandemic potential.
To register your interest for the webcast please contact Carl Curran carl.curran@infextx.com or Walbrook PR at infex@walbrookpr.com.
A recording of the presentation will be made available on the Company’s website after the event.